Citations

Mayo Clinic

Showing 10 of 108523 citations.

Explainable artificial intelligence in orthopedic surgery
Oettl, Felix C. , Oeding, Jacob F. , Samuelsson, Kristian , Oettl, Felix C. , Samuelsson, Kristian , Oeding, Jacob F

Journal of Experimental Orthopaedics | July 17, 2024 | Volume: 11 | Issue: 3 | Pages: No page available

10.1002/jeo2.12103 | PMID 39021892 Get It

Pituitary apoplexy is associated with concurrent or subsequent diagnosis of human immunodeficiency virus
Salmon, Mandy K. , White, Caitlin , Kharlip, Julia, Jackson, Christina , Lee, John Y. K. , Yoshor, Daniel , Kohanski, Michael A. , Adappa, Nithin D. , Douglas, Jennifer E , Salmon, Mandy K , Eide, Jacob G. , Kshirsagar, Rijul S. , Adappa, Nithin D.

World Journal of Otorhinolaryngology - Head and Neck Surgery | July 17, 2024 | Volume: 11 | Issue: 3 | Pages: 349-352

10.1002/wjo2.201 | PMID 40932922 Get It

Abstract Objective Pituitary apoplexy (PA) is a rare condition caused by hemorrhage or infarction of the pituitary gland with associated risk of cranial neuropathies, endocrinopathies, and even death. Human immunodeficiency virus (HIV) has been shown to have some association with pituitary apoplexy, however, large‐scale studies have not been performed. Methods A retrospective cohort study of subjects greater than 18 years of age was performed using the national TriNetX database. The general population was first compared with those undergoing treatment for PA to compare general demographics and incidence of HIV. The PA cohort was then substratified by HIV status and propensity matched by age and sex to evaluate differences in visual outcomes and endocrine metrics. Using the diagnosis of pituitary apoplexy as an index event, the rate of HIV diagnosis at the time of presentation or in the three months following treatment was calculated. Two‐tailed, unpaired t ‐tests were performed. Results A total 2066 patients were identified (902 HIV, 1158 controls). Those with HIV showed an increased rate of pituitary apoplexy (odds ratio [OR]: 19.8) versus healthy adults and were more likely to be younger and male. Among patients treated for pituitary apoplexy, patients with HIV were more likely to have increased thyroid stimulating hormone, reduced T 4 , and increased prolactin compared with healthy controls. There were no significant differences in visual outcomes between HIV positive and control patients. Importantly, 74% of patients did not carry a diagnosis of HIV on presentation but were diagnosed at the time of or in the three months following treatment for pituitary apoplexy. Conclusions Diagnosis and treatment of pituitary apoplexy shows a high rate of concurrent or subsequent diagnosis of HIV. Screening for HIV should be considered in patients undergoing treatment for pituitary apoplexy.
Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta
Egbe, A, Reddy, Yogesh N.V. , Ali, Ahmed E. , Younis, Ahmed , Nishimura, Rick , Egbe, Alexander C. , Borlaug, Barry A.

European Journal of Heart Failure | July 17, 2024 | Volume: 26 | Issue: 12 | Pages: 2595-2603

10.1002/ejhf.3379 | PMID 39014871 Get It

Aims There are similarities in the pathogenesis of cardiac remodelling and dysfunction in heart failure with preserved ejection fraction (HFpEF) and coarctation of aorta (COA). We hypothesized that clinical HFpEF would be highly prevalent in adults with COA, and that the presence of HFpEF would increase the risk of mortality in this population. The aim of this study was to define the clinical features, haemodynamics, and prognostic implications of HFpEF in COA. Methods and results Consecutive adults with repaired COA that underwent right heart catheterization were identified retrospectively. HFpEF was defined as heart failure symptoms (exertional dyspnoea or fatigue), preserved left ventricular ejection fraction ≥50%, and pulmonary artery wedge pressure at rest >15 mmHg. Of 99 COA patients, 32 (32%) had HFpEF. The correlates of HFpEF were obesity (adjusted odds ratio [OR] 4.15, 95% confidence interval [CI] 1.31–13.2), atrial fibrillation (adjusted OR 3.13, 95% CI 1.00–10.7), total arterial compliance index (adjusted OR 0.12, 95% CI 0.06–0.41 per 1 ml/mmHg*m 2 ), and pulmonary artery compliance index (adjusted OR 0.36, 95% CI 0.15–0.56 per 1 ml/mmHg*m 2 ). Of 99 patients, 24 (24%) died and 5 (5%) underwent heart transplant. The 10‐year cumulative incidence of death/transplant was higher in COA patients with HFpEF compared with patients without HFpEF (39% vs. 12%, p = 0.001). The presence of HFpEF was associated with increased risk of death/transplant (adjusted hazard ratio 1.68, 95% CI 1.16–3.11). Conclusions Heart failure with preserved ejection fraction is common in adults with COA and is associated with greater risk of death/transplant, emphasizing a pressing need for interventions to prevent and treat HFpEF in COA.
Artificial intelligence in cardiovascular medicine: clinical applications
Lüscher, Thomas F. , Wenzl, Florian A. , D’Ascenzo, Fabrizio , Friedman, Paul A. , Antoniades, Charalambos , Luescher, T F

European Heart Journal | July 17, 2024 | Volume: 45 | Issue: 40 | Pages: 4291-4304

10.1093/eurheartj/ehae465 | PMID 39158472 Get It

Abstract Clinical medicine requires the integration of various forms of patient data including demographics, symptom characteristics, electrocardiogram findings, laboratory values, biomarker levels, and imaging studies. Decision-making on the optimal management should be based on a high probability that the envisaged treatment is appropriate, provides benefit, and bears no or little potential harm. To that end, personalized risk–benefit considerations should guide the management of individual patients to achieve optimal results. These basic clinical tasks have become more and more challenging with the massively growing data now available; artificial intelligence and machine learning (AI/ML) can provide assistance for clinicians by obtaining and comprehensively preparing the history of patients, analysing face and voice and other clinical features, by integrating laboratory results, biomarkers, and imaging. Furthermore, AI/ML can provide a comprehensive risk assessment as a basis of optimal acute and chronic care. The clinical usefulness of AI/ML algorithms should be carefully assessed, validated with confirmation datasets before clinical use, and repeatedly re-evaluated as patient phenotypes change. This review provides an overview of the current data revolution that has changed and will continue to change the face of clinical medicine radically, if properly used, to the benefit of physicians and patients alike.
Use of corticosteroids for adult chronic pain interventions: sympathetic and peripheral nerve blocks, trigger point injections - guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, the Ameri
Benzon, Honorio T. , Elmofty, Dalia , Shankar, Hariharan , Rana, Maunak V., Shah, Shalini , Souza, Dmitri , Nagpal, Ameet , Abdi, Salahadin , Rafla, Christian , Eckmann, Maxim , Pino, Carlos A. , Rivera, Jessica , Schneider, Byron J. , Stout, Alison , Stengel, Angela D , Mina, Maged, FitzGerald, John , Hirsch, Joshua A , Manchikanti, Laxmaiah , Maus, Timothy P. , Chadwick, Andrea , Shah, Shalini , Nagpal, Ameet S , Abdi, Salahadin , Rafla, Christian , Doshi, Tina L , Hoang, Thanh D , Hunt, Christine , Pino, Carlos A , Schneider, Byron J , Stout, Alison , Stengel, Angela , FitzGerald, John D , Wasan, Ajay D , Provenzano, David Anthony , Narouze, Samer , Cohen, Steven P , Nelson, Ariana M , Shanthanna, Harsha , Benzon, Honorio T , Shankar, Hariharan , Abd-Elsayed, Alaa A , Doshi, Tina L , Rivera, Jessica, Wasan, Ajay D. , Provenzano, David , Narouze, Samer , Cohen, Steven P. , Nelson, Ariana M. , Shanthanna, Harsha

Regional Anesthesia & Pain Medicine | July 16, 2024 | Volume: 51 | Issue: 6 | Pages: 642-659

10.1136/rapm-2024-105593 | PMID 39019502 Get It

Background There is potential for adverse events from corticosteroid injections, including increase in blood glucose, decrease in bone mineral density and suppression of the hypothalamic–pituitary axis. Published studies note that doses lower than those commonly injected provide similar benefit. Methods Development of the practice guideline was approved by the Board of Directors of American Society of Regional Anesthesia and Pain Medicine with several other societies agreeing to participate. The scope of guidelines was agreed on to include safety of the injection technique (landmark-guided, ultrasound or radiology-aided injections); effect of the addition of the corticosteroid on the efficacy of the injectate (local anesthetic or saline); and adverse events related to the injection. Based on preliminary discussions, it was decided to structure the topics into three separate guidelines as follows: (1) sympathetic, peripheral nerve blocks and trigger point injections; (2) joints; and (3) neuraxial, facet, sacroiliac joints and related topics (vaccine and anticoagulants). Experts were assigned topics to perform a comprehensive review of the literature and to draft statements and recommendations, which were refined and voted for consensus (≥75% agreement) using a modified Delphi process. The United States Preventive Services Task Force grading of evidence and strength of recommendation was followed. Results This guideline deals with the use and safety of corticosteroid injections for sympathetic, peripheral nerve blocks and trigger point injections for adult chronic pain conditions. All the statements and recommendations were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Board of Directors of the participating societies also approved all the statements and recommendations. The safety of some procedures, including stellate blocks, lower extremity peripheral nerve blocks and some sites of trigger point injections, is improved by imaging guidance. The addition of non-particulate corticosteroid to the local anesthetic is beneficial in cluster headaches but not in other types of headaches. Corticosteroid may provide additional benefit in transverse abdominal plane blocks and ilioinguinal/iliohypogastric nerve blocks in postherniorrhaphy pain but there is no evidence for pudendal nerve blocks. There is minimal benefit for the use of corticosteroids in trigger point injections. Conclusions In this practice guideline, we provided recommendations on the use of corticosteroids in sympathetic blocks, peripheral nerve blocks, and trigger point injections to assist clinicians in making informed decisions.
Neurological Aspects of Substance Use Disorder: An Introduction
McArthur, Justin C. , Stitt, Derek , Stitt, Derek W

Seminars in Neurology | July 16, 2024 | Volume: 44 | Issue: 04 | Pages: 414-418

10.1055/s-0044-1787551 | PMID 39013393 Get It

A Familial Chromosome 4p16.3 Terminal Microdeletion That Does Not Cause Wolf-Hirschhorn (4p-) syndrome
Kahn, Eva , Lanpher, Brendan C. , Osundiji, Mayowa A.

No container title available | July 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4566567/v1 Get It

Abstract Chromosome 4p16.3 microdeletions are known to cause Wolf–Hirschhorn syndrome (WHS), which is characterized by a distinct craniofacial gestalt and multiple congenital malformations. The 4p16.3 region encompasses WHS critical region 1 (WHSCR1) and 2 (WHSCR2). The WHSCR contains several genes that have been implicated in the WHS phenotype including: WHS candidate 1 [WHSC1(aka NSD2, OMIM 602952)], WHS candidate 2 [WHSC2 (aka NELFA, OMIM 606026)], and LETM1 (OMIM 604407). Although several patients harboring 4p16.3 microdeletions that are associated with WHS phenotypes have been reported, the precise molecular underpinnings of WHS are subjects of active investigations. The potential role(s) of genes within the 4p16.3 are increasingly being investigated. Here we report the first documented case of 4p16.3 terminal microdeletion that is not associated with the characteristic WHS phenotype. We studied Individual A (7-months-old female) and her father, Individual B (27-year-old), who both carry a terminal 4p16.3 microdeletion (about 555kb) that is distal to the WHSCR [(WHSCR1) and (WHSCR2)], and does not include WHSC1, WHSC2, or LETM1. Overall, our findings expand the phenotypic spectrum associated with 4p16.3 microdeletions and suggest that, in some individuals, microdeletions within 4p16.3 region may not be sufficient to cause WHS.
Exome Sequencing Identifies Carriers of the Autosomal Dominant Cancer Predisposition Disorders Beyond Current Practice Guideline Recommendations
Samadder, N. Jewel , Gay, E. Greer , Lindpere, Vanda , Bublitz, Michelle L. , Bandel, Lorelei A. , Armasu, Sebastian M. , Ferber, Matthew J. , Klee, Eric W. , Larson, Nicholas B. , Kruisselbrink, Teresa , Egan, Jan B. , Kemppainen, Jennifer L., Bidwell, Jessa , McAllister, Tammy M., Walker, T'Nita S., Klint, Margaret A., Presutti, R. John , Summer-Bolster, Jolene M., Gay, Emily , Klee, Eric W , Larson, Nicholas B , Kruisselbrink, Teresa M, Bidwell, Jessa S , Anderson, Jennifer L. , Kunze, Katie L , Golafshar, Michael A. , Presutti, Richard J , Bobo, William V. , Sekulic, Aleksander , Willman, Cheryl , Lazaridis, Konstantinos N , Lindpere, Vanda , Vierkant, Robert A. , Anderson, Jennifer L., Kunze, Katie L. , Klint, Margaret, Willman, Cheryl L. , Lazaridis, Konstantinos N.

JCO Precision Oncology | July 16, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.24.00106 | PMID 39013133 Get It

PURPOSE The autosomal dominant cancer predisposition disorders hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) are genetic conditions for which early identification and intervention have a positive effect on the individual and public health. The goals of this study were to determine whether germline genetic screening using exome sequencing could be used to efficiently identify carriers of HBOC and LS. METHODS Participants were recruited from three geographically and racially diverse sites in the United States (Rochester, MN; Phoenix, AZ; Jacksonville, FL). Participants underwent Exome+ sequencing (Helix Inc, San Mateo, CA) and return of results for specific genetic findings: HBOC ( BRCA1 and BRCA1) and LS ( MLH1, MSH2, MSH6, PMS2, and EPCAM). Chart review was performed to collect demographics and personal and family cancer history. RESULTS To date, 44,306 participants have enrolled in Tapestry. Annotation and interpretation of all variants in genes for HBOC and LS resulted in the identification of 550 carriers (prevalence, 1.24%), which included 387 with HBOC (27.2% BRCA1, 42.8% BRCA2) and 163 with LS (12.3% MSH6, 8.8% PMS2, 4.5% MLH1, 3.8% MSH2, and 0.2% EPCAM). More than half of these participants (52.1%) were newly diagnosed carriers with HBOC and LS. In all, 39.2% of HBOC/LS carriers did not satisfy National Comprehensive Cancer Network (NCCN) criteria for genetic evaluation. NCCN criteria were less commonly met in underrepresented minority populations versus self-reported White race (51.5% v 37.5%, P = .028). CONCLUSION Our results emphasize the need for wider utilization of germline genetic sequencing for enhanced screening and detection of individuals who have LS and HBOC cancer predisposition syndromes.
Larger vegetable intake helps patients with constipation: socioeconomic analysis from United States–based matched cohorts
Suenghataiphorn, Thanathip , Suparan, Kanokphong , Lohawatcharagul, Tuntanut, Thongpiya, Jerapas , Suenghataiphorn, Thanathip , Danpanichkul, Pojsakorn , Kulthamrongsri, Narathorn , Polpichai, Natchaya

Baylor University Medical Center Proceedings | July 16, 2024 | Volume: 37 | Issue: 5 | Pages: 726-733

10.1080/08998280.2024.2375903 | PMID 39165819 Get It

Pulsatility of Pulmonary Artery Waveforms Before and After Left Ventricular Assist Device Is Associated With Right Ventricular Failure
Rosenbaum, Andrew , Behfar, Atta , Rossman, Timothy, Lundgren, Scott , Rosenbaum, Andrew N , Rossman, Timothy L, Lundgren, Scott W , Behfar, Atta

ASAIO Journal | July 16, 2024 | Volume: 71 | Issue: 3 | Pages: e38-e40

10.1097/mat.0000000000002272 | PMID 39023937 Get It